NEJ026 overall survival

Fei Liang expressed an important concern regarding lack of overall survival events (ie, deaths) for assessment of overall survival in the NEJ026 study1 and in the combined analysis of NEJ026 and the JO25567 study.2 We agree that overall survival is the most crucial factor to consider when evaluating benefits of drugs for patients with cancer. 既往NEJ026的结果显示出厄洛替尼联合贝伐单抗较厄洛替尼显示出明显的PFS获益，此次ASCO更新OS结果，在中位随访时间39.2个月后，A+T组中位生存较单纯EGFR-TKI组 … However, overall survival (OS) data were insufficient in the primary report because of the lack of death events.

However, the updated analysis of JO25567 study showed that this combination failed to improve overall survival (OS), and the OS data in NEJ026 study are still immature . Progression-free survival (PFS), PFS2, and overall survival (OS) were sequentially analyzed as primary end points according to a hierarchical sequential testing method. NEJ026試験：EGFR遺伝子変異陽性非小細胞肺癌に対するベバシズマブ＋エルロチニブ併用療法の最終生存解析. Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study. NEJ026: Final overall survival analysis of bevacizumabplus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.

NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. lung cancer. Kaplan-Meier curves with two-sided log-rank tests and Cox proportional hazards model with calculated hazard ratios and 95% confidence intervals were used to determine the survival difference.Of all patients, 149 patients received EGFR-TKIs monotherapy and 59 received EGFR-TKIs plus bevacizumab as first-line setting. Results At the median follow-up time of 35.6 months, However, whether this combination could benefit patients with multiple brain metastases (BrMs) remains undetermined.A total of 208 patients with EGFR-mutant NSCLC and multiple BrM (number >3, at least one of lesions was measurable) were retrospectively identified. EGFR-TKIs plus bevacizumab was associated with a significantly higher intracranial objective response rate (ORR, 66.1% vs. 41.6%, EGFR-TKIs plus bevacizumab prolonged not only PFS but also OS in patients with EGFR-mutant NSCLC and multiple BrMs when compared with EGFR-TKIs alone, indicating that this combination could be an alternative therapeutic option for those patients.These authors contributed equally to this article.We use cookies to help provide and enhance our service and tailor content and ads. The prevalence of Thr790Met mutations might have varied between both groups after study treatment, which would influence overall survival.

First Author: M.Maemondo NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.（2020 ASCO Virtual Scientific Program,Abstract No:9506） × 山田創 By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. Patients and methods: Progression-free survival (PFS) and OS were re-evaluated at the final data cut-off point (March 2017) for the entire population (n=80). Patients and methods Progression-free survival (PFS) and OS were re-evaluated at the final data cut-off point (March 2017) for the entire population (n=80). In contrast, the international BeTa trial (Lancet 2011;377:9780) did not show an overall survival benefit. Patients and methods Progression-free survival (PFS) and OS were re-evaluated at the final data cut-off point (March 2017) for the entire population (n=80). ScienceDirect ® is a registered trademark of Elsevier B.V. However, overall survival (OS) data were insufficient in the primary report because of the lack of death events.

.